EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population‐based case–control study in Sweden

Sarah Jonsson iD, Håkan Jonsson, Eva Lundin, Christel Häggström iD, Annika Idahl iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Sarah Jonsson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Pelvic Inflammatory Disease, Ovarian Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lion's Cancer Research Foundation in Northern Sweden, Insamlingsstiftelsen Medical faculty, Umea University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The resemblance between fallopian tube cells and serous borderline ovarian tumors (BOTs) suggests a potential origin link, with salpingitis proposed as a contributing factor in the pathogenesis of BOT. This study aimed to explore the potential association between pelvic inflammatory disease (PID) and the risk of developing BOT. A national population‐based case–control study in Sweden included women with BOT between 1999 and 2020 and 10 matched controls. Data from nationwide registers were analyzed using conditional logistic regression, adjusting for age, residential district, educational level and parity. Among 4782 cases and 45,167 controls, 2.0% of cases and 1.3% of controls had a history of PID. Previous PID was associated with an increased risk of BOT overall (aOR, 1.48; 95% CI, 1.19–1.85). Significant association was observed with serous tumors (aOR, 1.76; 95% CI, 1.36–2.29), while not with mucinous tumors (aOR, 0.95; 95% CI, 0.60–1.49). A dose–response relationship between number of PID episodes and serous BOT risk was noted ( P trend < .001). This study demonstrates that PID is associated with increased risk of serous BOT, with a dose response relationship. The study highlights the potential serious implications of upper reproductive tract infections and inflammation. This underscores the need for further investigation of biological mechanisms and possible impact of PID on serous BOT development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pelvic Inflammatory DiseaseOvarian NeoplasmsHumansFemaleCase-Control StudiesSwedenMiddle AgedAdultAgedRisk FactorsYoung AdultRegistries

Stichwörter der Autor:innen

borderline ovarian tumorpelvic inflammatory diseasepopulation‐based case–control study

Autor:innen und Institutionen

  • Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
  • Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden.
  • Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
  • Department of Diagnostics and Intervention, Registry Centre North, Umeå University, Umeå, Sweden.

ORCID-Profile: Sarah Jonsson, Christel Häggström, Annika Idahl

Förderung

  • Lion's Cancer Research Foundation in Northern Sweden
  • Insamlingsstiftelsen Medical faculty, Umea University

Zitieren

APA

Jonsson, S., Jonsson, H., Lundin, E., Häggström, C., & Idahl, A. (2025). Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population‐based case–control study in Sweden. International Journal of Cancer. https://doi.org/10.1002/ijc.35180

Vancouver

Jonsson S, Jonsson H, Lundin E, Häggström C, Idahl A. Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population‐based case–control study in Sweden. International Journal of Cancer. 2025. doi:10.1002/ijc.35180

BibTeX
@article{Jonsson2025,
  author = {Jonsson, Sarah and Jonsson, Håkan and Lundin, Eva and Häggström, Christel and Idahl, Annika},
  title = {Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population‐based case–control study in Sweden},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35180}
}
Kostenlos starten →